SG10201908584SA - Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease - Google Patents

Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease

Info

Publication number
SG10201908584SA
SG10201908584SA SG10201908584SA SG10201908584SA SG 10201908584S A SG10201908584S A SG 10201908584SA SG 10201908584S A SG10201908584S A SG 10201908584SA SG 10201908584S A SG10201908584S A SG 10201908584SA
Authority
SG
Singapore
Prior art keywords
statins
formulations
risk
treating
reducing
Prior art date
Application number
Inventor
Roger NEWTON
Noah Rosenberg
Diane Macdougall
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of SG10201908584SA publication Critical patent/SG10201908584SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

FixedDose Combinations And Formulations Comprising ETC And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease
SG10201908584S 2015-03-16 2016-03-16 Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease SG10201908584SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562133739P 2015-03-16 2015-03-16
US201662277403P 2016-01-11 2016-01-11

Publications (1)

Publication Number Publication Date
SG10201908584SA true SG10201908584SA (en) 2019-11-28

Family

ID=56919968

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707579RA SG11201707579RA (en) 2015-03-16 2016-03-16 Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk
SG10201908584S SG10201908584SA (en) 2015-03-16 2016-03-16 Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201707579RA SG11201707579RA (en) 2015-03-16 2016-03-16 Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk

Country Status (24)

Country Link
US (2) US11116739B2 (en)
EP (2) EP4327887A2 (en)
JP (3) JP7296190B2 (en)
CN (3) CN116832164A (en)
AU (2) AU2016233257B2 (en)
BR (1) BR112017019728A2 (en)
CA (1) CA2978180A1 (en)
CL (1) CL2017002334A1 (en)
DK (1) DK3270909T3 (en)
FI (1) FI3270909T3 (en)
HK (1) HK1245643A1 (en)
HR (1) HRP20240098T1 (en)
IL (2) IL292829A (en)
LT (1) LT3270909T (en)
MA (1) MA41793A (en)
MX (2) MX2017011500A (en)
PH (1) PH12017501659A1 (en)
PT (1) PT3270909T (en)
RU (1) RU2765218C2 (en)
SG (2) SG11201707579RA (en)
SI (1) SI3270909T1 (en)
UA (1) UA125371C2 (en)
WO (1) WO2016149405A1 (en)
ZA (1) ZA201706945B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2022102472A (en) 2015-03-13 2022-03-15 Эсперион Терапеутикс, Инк. FIXED COMBINATIONS AND COMPOSITIONS CONTAINING ETC-1002 AND EZETIMIB AND METHODS FOR THE TREATMENT OR REDUCTION OF THE RISK OF CARDIOVASCULAR DISEASE DEVELOPMENT
MA41793A (en) 2015-03-16 2018-01-23 Esperion Therapeutics Inc FIXED DOSE ASSOCIATIONS INCLUDING ETC1002 AND ONE OR MORE STATINS TO TREAT OR REDUCE A CARDIOVASCULAR RISK
US20210361618A1 (en) * 2017-02-08 2021-11-25 Esperion Therapeutics, Inc. Triplet combination formulations and methods for treating or reducing the risk of cardiovascular disease
MX2020008527A (en) * 2018-02-16 2020-09-18 Esperion Therapeutics Inc Sustained release formulations of bempedoic acid.
WO2019179494A1 (en) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 Substituted pentadecanedioic acid compound and pharmaceutical composition and use thereof
WO2020041799A1 (en) * 2018-08-24 2020-02-27 Esperion Therapeutics, Inc. Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
JP2021535136A (en) * 2018-08-27 2021-12-16 エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. Combination drug formulation for treating patients with cardiovascular disease and related conditions
CN112437765A (en) 2019-06-21 2021-03-02 艾斯柏伦治疗公司 Salt forms of bipedac acid and methods of use thereof
CN113134086A (en) * 2020-01-20 2021-07-20 深圳市长卿医学研究院 Pharmaceutical composition for reducing blood fat

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
US3441605A (en) 1965-02-17 1969-04-29 Wallace & Tiernan Inc Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
FR1545224A (en) 1966-12-21 1968-11-08 Geigy Ag J R Process for preparing sebacic acid
GB1196595A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Lactone
GB1196594A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Improvements in and relating to the production of Sebacic Acid
GB1196598A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a Ketosebacic Acid
GB1196596A (en) 1966-12-21 1970-07-01 Geigy Uk Ltd Preparation of a hydroxysebacic acid
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4281200A (en) 1979-08-30 1981-07-28 The Dow Chemical Company Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
JPS5639033A (en) 1979-09-04 1981-04-14 Kao Corp Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IT1164254B (en) 1983-05-30 1987-04-08 Luso Farmaco Inst 3- (3-HYDROXYBUTOXY) -1-BUTANOL AND ITS PREPARATION METHOD
JPS59232811A (en) 1983-06-16 1984-12-27 Sumitomo Chem Co Ltd Preparation of aromatic polyamide-imide resin molding
JPS60136512A (en) 1983-12-26 1985-07-20 Eisai Co Ltd Remedy and preventive for hyperlipemia
DE3423166A1 (en) 1984-06-22 1986-01-02 Epis S.A., Zug ALPHA, OMEGA DICARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4896344A (en) 1984-10-15 1990-01-23 Grady John K X-ray video system
US4634119A (en) 1985-07-11 1987-01-06 Pesthy Paul K Resilient exercise machine with body support platform
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US4758880A (en) 1987-03-27 1988-07-19 The Grass Valley Group, Inc. Video matte generator
JP2999579B2 (en) 1990-07-18 2000-01-17 武田薬品工業株式会社 DNA and its uses
US5254589A (en) 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5420339A (en) 1993-11-22 1995-05-30 Warner-Lambert Company Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
JP2937012B2 (en) 1994-04-08 1999-08-23 時久 増田 Method and apparatus for manufacturing rectangular tubular packaging bag
US5578639A (en) 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5504073A (en) 1994-07-01 1996-04-02 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
SE9500778D0 (en) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
DE69636783T2 (en) 1995-11-02 2007-10-18 Warner-Lambert Co. Llc METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6093744A (en) 1997-04-21 2000-07-25 Warner-Lambert Company N-acyl sulfamic acid esters useful as hypocholesterolemic agents
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
BR9815039A (en) 1997-11-25 2001-03-20 Warner Lambert Co Inhibition of lipoprotein oxidation
EP1137634B1 (en) 1998-12-07 2005-06-15 Schering Corporation Process for the synthesis of azetidinones
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
JP2002541129A (en) 1999-04-01 2002-12-03 エスペリオン セラピューティクス インコーポレイテッド Ether compounds, compositions, and uses thereof
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1326822A2 (en) 2000-10-11 2003-07-16 Esperion Therapeutics Inc. Ketone compounds and compositions for cholesterol management and related uses
CN1479721A (en) 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN101426763A (en) 2000-10-11 2009-05-06 埃斯佩里安医疗公司 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
IL155215A0 (en) 2000-10-11 2003-11-23 Esperion Therapeutics Inc Ether compounds and compositions for cholesterol management and related uses
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7053046B2 (en) 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US7335689B2 (en) 2003-01-23 2008-02-26 Esperion Therapeutics, Inc. Dihydroxyl compounds and compositions for cholesterol management and related uses
DE10352659B4 (en) 2003-11-11 2007-09-13 Ratiopharm Gmbh Process for the preparation of statins and tetrahydropyranone derivatives for use in the process
US20050171080A1 (en) 2003-12-23 2005-08-04 Dr. Reddy's Laboratories, Inc. Polymorphs of ezetimibe and process for preparation thereof
US7705177B2 (en) 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
JP4553181B2 (en) 2004-03-25 2010-09-29 株式会社サタケ Pesticide residue analysis method
US7194579B2 (en) 2004-04-26 2007-03-20 Sun Microsystems, Inc. Sparse multi-component files
PE20070824A1 (en) 2005-11-15 2007-08-24 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION CONTAINING LAPAQUISTAT AND EZETIMIBE IN THE TREATMENT OF HYPERLIPIDEMIA
RU2015127794A (en) * 2007-03-24 2018-12-21 Касл Терапьютикс, ЭлЭлСи Introduction of antisense oligonucleotides complementary to human apolipoprotein B
US8481084B2 (en) * 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
US8209479B2 (en) 2007-07-18 2012-06-26 Google Inc. Memory circuit system and method
ES2639995T3 (en) 2007-12-10 2017-10-31 Ratiopharm Gmbh Pharmaceutical formulation comprising ezetimibe
EP2168573A1 (en) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
ATE536172T1 (en) 2009-03-13 2011-12-15 Sanovel Ilac Sanayi Ve Ticaret As EZETIMIBE COMPOSITIONS
CA2812109A1 (en) 2010-09-20 2012-03-29 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
AR083417A1 (en) 2010-10-14 2013-02-21 Novartis Ag PHARMACEUTICAL COMPOSITIONS CONTAINING AN INHIBITOR DGAT1
AR086675A1 (en) 2011-06-14 2014-01-15 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF INHIBITORS OF DIPEPTIDIL PEPTIDASA-4 WITH SIMVASTATIN
CN110025608A (en) * 2012-01-06 2019-07-19 燿石治疗公司 The method for reducing risk of cardiovascular diseases
WO2013158810A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release pharmaceutical compositions with abuse deterrent properties
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2931718B1 (en) 2012-12-17 2019-01-16 Merck Sharp & Dohme Corp. Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
RU2022102472A (en) 2015-03-13 2022-03-15 Эсперион Терапеутикс, Инк. FIXED COMBINATIONS AND COMPOSITIONS CONTAINING ETC-1002 AND EZETIMIB AND METHODS FOR THE TREATMENT OR REDUCTION OF THE RISK OF CARDIOVASCULAR DISEASE DEVELOPMENT
MA41793A (en) 2015-03-16 2018-01-23 Esperion Therapeutics Inc FIXED DOSE ASSOCIATIONS INCLUDING ETC1002 AND ONE OR MORE STATINS TO TREAT OR REDUCE A CARDIOVASCULAR RISK
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator

Also Published As

Publication number Publication date
JP2021102615A (en) 2021-07-15
IL292829A (en) 2022-07-01
UA125371C2 (en) 2022-03-02
EP3270909B1 (en) 2023-11-01
US20220110904A1 (en) 2022-04-14
RU2765218C2 (en) 2022-01-26
CL2017002334A1 (en) 2018-03-16
SI3270909T1 (en) 2024-03-29
CN107530308A (en) 2018-01-02
IL254202B (en) 2022-06-01
KR20180006889A (en) 2018-01-19
AU2016233257B2 (en) 2021-05-27
JP2023062198A (en) 2023-05-02
JP7296190B2 (en) 2023-06-22
CA2978180A1 (en) 2016-09-22
US11116739B2 (en) 2021-09-14
RU2017136295A (en) 2019-04-16
MX2022005372A (en) 2022-05-19
PH12017501659A1 (en) 2018-03-12
LT3270909T (en) 2024-02-26
CN116832164A (en) 2023-10-03
MA41793A (en) 2018-01-23
AU2021221908A1 (en) 2021-09-23
PT3270909T (en) 2024-02-05
HK1245643A1 (en) 2018-08-31
JP2018508551A (en) 2018-03-29
US20180078518A1 (en) 2018-03-22
SG11201707579RA (en) 2017-10-30
BR112017019728A2 (en) 2018-05-22
WO2016149405A1 (en) 2016-09-22
AU2016233257A1 (en) 2017-11-02
HRP20240098T1 (en) 2024-04-12
EP4327887A2 (en) 2024-02-28
FI3270909T3 (en) 2024-02-01
EP3270909A4 (en) 2018-08-01
IL254202A0 (en) 2017-10-31
CN114159564A (en) 2022-03-11
MX2017011500A (en) 2018-03-26
EP3270909A1 (en) 2018-01-24
ZA201706945B (en) 2022-02-23
DK3270909T3 (en) 2024-01-29
RU2017136295A3 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
HK1258205A1 (en) Compositions and methods for the treatment of hemoglobinopathies
IL272948B1 (en) Enpp1 inhibitors and their use for the treatment of cancer
SG10201908584SA (en) Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease
IL273959A (en) Methods and compositions for the treatment of rare diseases
IL258854A (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
ZA201706919B (en) Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
HK1259545A1 (en) Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
IL266486A (en) Pharmaceutical compositions and methods for the treatment of cancer
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
ZA201808232B (en) Compositions and methods for the treatment of cancer
PH12016501838A1 (en) Compounds and their methods of use
HK1255695A1 (en) Composition and methods for the treatment of blepharoptosis
IL272147A (en) Methods and compositions for the treatment of cancer
ZA201802201B (en) Novel formulation and treatment methods
SG11201706369PA (en) Compositions and methods for the treatment of mucositis